臓器保存の世界市場：保存液タイプ別、技術別、臓器別、エンドユーザー別 - 予測（～2030年）

世界の臓器保存の市場規模は、2025年の20万米ドルから2030年までに3億米ドルに達すると予測され、予測期間にCAGRで6.8%の成長が見込まれます。

臓器保存液とデバイスの主な目的は、臓器の調達から移植までの間、臓器の生存能力と機能性を維持することです。世界の臓器移植件数の増加、保存技術の進歩、低温・常温機械灌流システムなどの特殊保存ソリューションの導入など、複数の要因がこの市場の一貫した成長を後押ししています。末期腎不全や肝不全などの慢性疾患の罹患率の増加が臓器移植の需要を促進しており、その結果、効果的な保存技術へのニーズが高まっています。

保存液タイプ別では、2024年にウィスコンシン大学（UW）セグメントが最大の市場シェアを占めました。

市場は保存液タイプ別にUW、Custodiol HTK、Perfadex、その他の保存液に分類されます。2024年、ウィスコンシン大学（UW）保存液が、肝臓、腎臓、膵臓のような臓器の温存に有効であることが証明されるなど、高い採用率と特徴により、最大の市場シェアを占めました。UW保存液は最初に導入された細胞内臓器保存液であり、臓器保存の世界基準として広く認められています。その確立された臨床成績と信頼性により、移植外科医や医療施設の間で好ましい選択肢としての地位を確立しています。

技術別では、常温機械灌流セグメントが予測期間にもっとも高いCAGRを記録する見込みです。

常温機械灌流セグメントが予測期間にもっとも高いCAGRで成長する見込みです。この技術は、正常な体温を維持し、必須栄養素と酸素を臓器に供給することによって、自然の生理的条件をシミュレートします。保存期間を通じて細胞機能と代謝をサポートします。常温灌流は臓器の生存能力を維持し、特に肝移植における炎症反応や虚血障害を最小化するのに役立ちます。常温灌流は、移植片の再生を向上させる上で不可欠であり、高齢者や合併症を持つ人などの拡大基準ドナーが関与する移植症例における良好な転帰と関連しています。その結果、移植片の長期生存と機能を最適化しようとする移植専門家の間で、その関連性が高まっています。

臓器タイプ別では、肺セグメントが予測期間にもっとも高いCAGRで成長する見込みです。

肺セグメントが予測期間にもっとも高いCAGRで成長する見込みです。肺移植は、慢性閉塞性肺疾患（COPD）、特発性肺線維症、嚢胞性線維症などの末期肺疾患患者にとって好ましい治療法とされており、これらはすべてこのセグメントの成長に寄与しています。成人患者における末期肺疾患のその他の一般的な原因には、α1アンチトリプシン欠損症や肺高血圧症などがあります。呼吸器疾患の増加に伴い、肺移植を必要とする患者の数は増加すると予測され、肺移植の需要が促進されています。さらに、移植片の生存期間と長期的な移植片機能の進歩により、肺移植は重要かつしばしば救命的な治療オプションとして確立されています。

エンドユーザー別では、専門クリニックセグメントが予測期間にもっとも高いCAGRで成長する見込みです。

臓器保存市場は、エンドユーザーによって臓器移植センター、病院、専門クリニックに区分されます。臓器保存市場では、移植手術や術後ケアにおける専門クリニックの役割が高まっていることから、専門クリニックセグメントがもっとも高いCAGRで成長すると予測されます。これらのクリニックは、臓器保存のニーズに合わせて、集中的な専門知識、短い所要時間、先進技術を提供しています。さらに、専門的なケアに対する患者の選好の高まりや民間医療投資の増加が、このセグメントにおける成長をさらに加速させています。

地域別では、アジア太平洋が予測期間にもっとも高いCAGRで成長する見込みです。

アジア太平洋が予測期間にもっとも高いCAGRで成長する見込みです。このセグメントの高い成長率は主に、有利な政府政策、社会的認知度の向上、臓器提供件数の増加の組み合わせによるものです。例えば中国では、市民教育の強化、動員活動、臓器移植技術の進歩により、臓器提供率が向上しています。一方、インドは医療インフラの急速な開発が市場成長を支え、メディカルツーリズムを促進しています。宗教的な懸念はありますが、日本では臓器提供への意欲の向上による臓器提供率の改善が見られます。

当レポートでは、世界の臓器保存市場について調査分析し、主な促進要因と抑制要因、競合情勢、将来の動向などの情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要な知見

• 臓器保存市場における企業にとって魅力的な機会
• アジア太平洋の臓器保存市場：保存液別、国別
• 臓器保存市場：地理的成長機会
• 臓器保存市場：地域別（2023年～2030年）
• 臓器保存市場：先進国市場と新興国市場

第5章 市場の概要

• イントロダクション
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
  • 課題
• エコシステム分析
• バリューチェーン分析
• 価格分析
• サプライチェーン分析
• 特許分析
  • 臓器保存市場における特許公報の動向
  • 臓器保存特許の主な出願企業
  • 管轄分析：臓器保存市場における特許の主な出願国
• 技術分析
  • 主要技術
  • 隣接技術
  • 補完技術
• 貿易分析
  • 輸入データ
  • 輸出データ
• 主な会議とイベント（2025年～2026年）
• 規制情勢
  • 規制分析
  • 規制機関、政府機関、その他の組織
• ポーターのファイブフォース分析
• 主なステークホルダーと購入基準
• 顧客ビジネスに影響を与える動向/混乱
• ケーススタディ分析
• 投資と資金調達のシナリオ
• 償還シナリオ
• 臓器保存市場に対するAIの影響
• 臓器保存市場におけるエンドユーザーの期待
• 2025年の米国関税の影響
  • イントロダクション
  • 主な関税率
  • 価格の影響の分析
  • エンドユーザーに対する影響

第6章 臓器保存市場：保存液別

• イントロダクション
• UW
• Custodiol HTK
• Perfadex
• その他の保存液

第7章 臓器保存市場：技術別

• イントロダクション
• 静的冷蔵保存
• 低温機械灌流
• 常温機械灌流

第8章 臓器保存市場：臓器別

• イントロダクション
• 腎臓
• 肝臓
• 肺
• 心臓
• その他の臓器

第9章 臓器保存市場：エンドユーザー別

• イントロダクション
• 臓器移植センター
• 病院
• 専門クリニック

第10章 臓器保存市場：地域別

• イントロダクション
• 北米
  • マクロ経済の見通し
  • 米国
  • カナダ
• 欧州
  • マクロ経済の見通し
  • ドイツ
  • フランス
  • 英国
  • スペイン
  • イタリア
  • その他の欧州
• アジア太平洋
  • マクロ経済の見通し
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • マクロ経済の見通し
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
• 中東・アフリカ
• GCC諸国

第11章 競合情勢

• 概要
• 主要参入企業の戦略/強み
• 収益分析（2022年～2024年）
• 市場シェア分析
• 企業の評価マトリクス：主要企業（2024年）
• 企業の評価マトリクス：スタートアップ/中小企業（2024年）
• 企業の評価と財務指標
• ブランド/製品の比較
• 競合シナリオ

第12章 企業プロファイル

• 主要企業
  • PARAGONIX TECHNOLOGIES, INC.
  • XVIVO PERFUSION AB
  • DR. FRANZ KOHLER CHEMIE GMBH
  • ESSENTIAL PHARMACEUTICALS, LLC (SUBSIDIARY OF ACCORD HEALTHCARE)
  • TRANSMEDICS, INC.
  • ORGANOX LIMITED
  • 21ST CENTURY MEDICINE
  • BIOLIFE SOLUTIONS, INC.
  • BRIDGE TO LIFE LIMITED
  • WATERS MEDICAL SYSTEMS LLC
• その他の企業
  • SHANGHAI GENEXT MEDICAL TECHNOLOGY CO., LTD.
  • PRESERVATION SOLUTIONS, INC.
  • CARNAMEDICA
  • TRANSPLANT BIOMEDICALS
  • INSTITUT GEORGES LOPEZ
  • GLOBAL TRANSPLANT SOLUTIONS
  • AVIONORD
  • ORGAN PRESERVATION SOLUTIONS LTD.
  • EBERS
  • S.A.L.F.
  • BIOCHEFA
  • VASCULAR PERFUSION SOLUTIONS, INC.
  • TX INNOVATIONS
  • TAIYO NIPPON SANSO CORPORATION
  • X-THERMA, INC.

第13章 付録

List of Tables

• TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021-2024
• TABLE 2 GROWTH IN GERIATRIC POPULATION (ABOVE 65 AGE GROUP), BY REGION, 2019 VS. 2050 (MILLION)
• TABLE 3 NUMBER OF ORGAN DONATIONS, 2020
• TABLE 4 COST OF SURGICAL PROCEDURES: US VS. INDIA (USD)
• TABLE 5 AVERAGE SELLING PRICE RANGE OF ORGAN PRESERVATION SOLUTIONS, BY KEY PLAYERS, 2023-2024
• TABLE 6 AVERAGE SELLING PRICE RANGE OF CUSTODIOL SOLUTIONS FOR ORGAN PRESERVATION SOLUTIONS IN KEY REGIONS, 2022-2024
• TABLE 7 ORGAN PRESERVATION MARKET: LIST OF MAJOR PATENTS, 2020-2021
• TABLE 8 IMPORT DATA OF ORGAN PRESERVATION FOR HS CODE 300640, BY COUNTRY, 2019-2023 (USD THOUSAND)
• TABLE 9 EXPORT DATA OF ORGAN PRESERVATION FOR HS CODE 300640, BY COUNTRY, 2019-2023 (USD THOUSAND)
• TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 SOLUTIONS (%)
• TABLE 15 KEY BUYING CRITERIA FOR TOP 3 SOLUTIONS
• TABLE 16 CASE STUDY 1: PRESERVATION OF MARGINAL LIVER USING NORMOTHERMIC MACHINE PERFUSION (NMP)
• TABLE 17 CASE STUDY 2: HYPOTHERMIC MACHINE PERFUSION FOR EXTENDED CRITERIA KIDNEY TRANSPLANT
• TABLE 18 CASE STUDY 3: USE OF PORTABLE NORMOTHERMIC PERFUSION FOR HEART TRANSPLANTATION
• TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES
• TABLE 20 ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 21 ORGAN PRESERVATION SOLUTIONS MARKET, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 22 ORGAN PRESERVATION MARKET FOR UW SOLUTIONS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 23 ORGAN PRESERVATION MARKET FOR CUSTODIOL HTK SOLUTIONS, BY COUNTRY/ REGION, 2023-2030 (USD MILLION)
• TABLE 24 ORGAN PRESERVATION MARKET FOR PERFADEX SOLUTIONS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 25 OTHER ORGAN PRESERVATION SOLUTIONS MARKET, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 26 COMPARISON OF METHODS USED FOR ORGAN PRESERVATION
• TABLE 27 ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 28 ORGAN PRESERVATION TECHNIQUE MARKET, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 29 STATIC COLD STORAGE: ADVANTAGES AND DISADVANTAGES
• TABLE 30 ORGAN PRESERVATION MARKET FOR STATIC COLD STORAGE, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 31 HYPOTHERMIC MACHINE PERFUSION: ADVANTAGES AND DISADVANTAGES
• TABLE 32 ORGAN PRESERVATION MARKET FOR HYPOTHERMIC MACHINE PERFUSION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 33 NORMOTHERMIC MACHINE PERFUSION: ADVANTAGES AND DISADVANTAGES
• TABLE 34 ORGAN PRESERVATION MARKET FOR NORMOTHERMIC MACHINE PERFUSION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 35 ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 36 KIDNEY PRESERVATION MARKET, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 37 LIVER PRESERVATION MARKET, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 38 LUNG PRESERVATION MARKET, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 39 HEART PRESERVATION MARKET, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 40 OTHER ORGAN PRESERVATION MARKET, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 41 ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 42 ORGAN PRESERVATION MARKET FOR ORGAN TRANSPLANT CENTERS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 43 ORGAN PRESERVATION MARKET FOR HOSPITALS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 44 ORGAN PRESERVATION MARKET FOR SPECIALTY CLINICS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
• TABLE 45 ORGAN PRESERVATION MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 46 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 47 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 48 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 49 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 50 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 51 US: KEY MACROINDICATORS
• TABLE 52 WAITING LIST FOR ORGAN TRANSPLANTS AS OF JANUARY 2022
• TABLE 53 US: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 54 US: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 55 US: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 56 US: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 57 CANADA: KEY MACROINDICATORS
• TABLE 58 CANADA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 59 CANADA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 60 CANADA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 61 CANADA: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 62 EUROPE: ORGAN PRESERVATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 63 EUROPE: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 64 EUROPE: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 65 EUROPE: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 66 EUROPE: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 67 GERMANY: KEY MACROINDICATORS
• TABLE 68 GERMANY: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 69 GERMANY: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 70 GERMANY: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 71 GERMANY: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 72 FRANCE: KEY MACROINDICATORS
• TABLE 73 FRANCE: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 74 FRANCE: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 75 FRANCE: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 76 FRANCE: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 77 UK: KEY MACROINDICATORS
• TABLE 78 TOTAL NUMBER OF PATIENTS ON ACTIVE ORGAN TRANSPLANT WAITING LIST IN UK (AS OF APRIL 8, 2021)
• TABLE 79 UK: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 80 UK: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 81 UK: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 82 UK: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 83 SPAIN: KEY MACROINDICATORS
• TABLE 84 SPAIN: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 85 SPAIN: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 86 SPAIN: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 87 SPAIN: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 88 ITALY: KEY MACROINDICATORS
• TABLE 89 ITALY: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 90 ITALY: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 91 ITALY: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 92 ITALY: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 93 REST OF EUROPE: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 94 REST OF EUROPE: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 95 REST OF EUROPE: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 96 REST OF EUROPE: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 97 ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 98 ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 99 ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 100 ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 101 ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 102 CHINA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 103 CHINA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 104 CHINA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 105 CHINA: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 106 TOTAL NUMBER OF PATIENTS ON ORGAN TRANSPLANT WAITING LIST IN JAPAN (AS OF MARCH 31, 2021)
• TABLE 107 JAPAN: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 108 JAPAN: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 109 JAPAN: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 110 JAPAN: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 111 INDIA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 112 INDIA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 113 INDIA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 114 INDIA: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 115 AUSTRALIA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 116 AUSTRALIA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 117 AUSTRALIA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 118 AUSTRALIA: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 119 SOUTH KOREA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 120 SOUTH KOREA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 121 SOUTH KOREA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 122 SOUTH KOREA: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 123 REST OF ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 124 REST OF ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 125 REST OF ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 126 REST OF ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 127 LATIN AMERICA: ORGAN PRESERVATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 128 LATIN AMERICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 129 LATIN AMERICA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 130 LATIN AMERICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 131 LATIN AMERICA: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 132 BRAZIL: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 133 BRAZIL: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 134 BRAZIL: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 135 BRAZIL: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 136 MEXICO: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 137 MEXICO: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 138 MEXICO: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 139 MEXICO: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 140 REST OF LATIN AMERICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 141 REST OF LATIN AMERICA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 142 REST OF LATIN AMERICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 143 REST OF LATIN AMERICA: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 144 MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 145 MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 146 MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 147 MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 148 GCC COUNTRIES: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
• TABLE 149 GCC COUNTRIES: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023-2030 (USD MILLION)
• TABLE 150 GCC COUNTRIES: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023-2030 (USD MILLION)
• TABLE 151 GCC COUNTRIES: ORGAN PRESERVATION MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 152 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORGAN PRESERVATION MARKET
• TABLE 153 ORGAN PRESERVATION MARKET: DEGREE OF COMPETITION
• TABLE 154 ORGAN PRESERVATION MARKET: SOLUTION FOOTPRINT
• TABLE 155 ORGAN PRESERVATION MARKET: TECHNIQUE FOOTPRINT
• TABLE 156 ORGAN PRESERVATION MARKET: END USER FOOTPRINT
• TABLE 157 ORGAN PRESERVATION MARKET: REGION FOOTPRINT
• TABLE 158 ORGAN PRESERVATION MARKET: LIST OF KEY STARTUPS/SMES
• TABLE 159 ORGAN PRESERVATION MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
• TABLE 160 ORGAN PRESERVATION MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 161 ORGAN PRESERVATION MARKET: DEALS, JANUARY 2021-JUNE 2025
• TABLE 162 ORGAN PRESERVATION MARKET: OTHER DEVELOPMENTS, JANUARY 2021-JUNE 2025
• TABLE 163 PARAGONIX TECHNOLOGIES, INC.: COMPANY OVERVIEW
• TABLE 164 PARAGONIX TECHNOLOGIES, INC.: PRODUCTS OFFERED
• TABLE 165 PARAGONIX TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2021-MAY 2025
• TABLE 166 PARAGONIX TECHNOLOGIES, INC.: DEALS, JANUARY 2021-MAY 2025
• TABLE 167 PARAGONIX TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2025
• TABLE 168 XVIVO PERFUSION AB: COMPANY OVERVIEW
• TABLE 169 XVIVO PERFUSION AB: PRODUCTS OFFERED
• TABLE 170 XVIVO PERFUSION AB: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2025
• TABLE 171 XVIVO PERFUSION AB: DEALS, JANUARY 2021-MAY 2025
• TABLE 172 DR. FRANZ KOHLER CHEMIE GMBH: COMPANY OVERVIEW
• TABLE 173 DR. FRANZ KOHLER CHEMIE GMBH: PRODUCTS OFFERED
• TABLE 174 ESSENTIAL PHARMACEUTICALS, LLC: COMPANY OVERVIEW
• TABLE 175 ESSENTIAL PHARMACEUTICALS, LLC: PRODUCTS OFFERED
• TABLE 176 TRANSMEDICS, INC.: COMPANY OVERVIEW
• TABLE 177 TRANSMEDICS, INC.: PRODUCTS OFFERED
• TABLE 178 TRANSMEDICS, INC.: PRODUCT LAUNCHES & APPROVALS
• TABLE 179 TRANSMEDICS, INC.: DEALS
• TABLE 180 ORGANOX LIMITED: COMPANY OVERVIEW
• TABLE 181 ORGANOX LIMITED: PRODUCTS OFFERED
• TABLE 182 ORGANOX LIMITED: PRODUCT LAUNCHES & APPROVALS
• TABLE 183 ORGANOX LIMITED: DEALS
• TABLE 184 21ST CENTURY MEDICINE: COMPANY OVERVIEW
• TABLE 185 21ST CENTURY MEDICINE: PRODUCTS OFFERED
• TABLE 186 BIOLIFE SOLUTIONS, INC.: COMPANY OVERVIEW
• TABLE 187 BIOLIFE SOLUTIONS, INC.: PRODUCTS OFFERED
• TABLE 188 BIOLIFE SOLUTIONS, INC.: PRODUCT LAUNCHES, JANUARY 2021-MAY 2025
• TABLE 189 BIOLIFE SOLUTIONS, INC.: DEALS, JANUARY 2021-MAY 2025
• TABLE 190 BRIDGE TO LIFE LIMITED: COMPANY OVERVIEW
• TABLE 191 BRIDGE TO LIFE LIMITED: PRODUCTS OFFERED
• TABLE 192 BRIDGE TO LIFE LIMITED: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2025
• TABLE 193 BRIDGE TO LIFE LIMITED: DEALS, JANUARY 2021-MAY 2025
• TABLE 194 WATERS MEDICAL SYSTEMS LLC: COMPANY OVERVIEW
• TABLE 195 WATERS MEDICAL SYSTEMS LLC: PRODUCTS OFFERED

List of Figures

• FIGURE 1 ORGAN PRESERVATION MARKET: RESEARCH DESIGN
• FIGURE 2 LIST OF PRIMARY SOURCES
• FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
• FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
• FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: XVIVO PERFUSION AB (2024)
• FIGURE 8 ILLUSTRATIVE EXAMPLE OF PROCEDURE-BASED MARKET ESTIMATION
• FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: ORGAN PRESERVATION MARKET (2024)
• FIGURE 10 TOP-DOWN APPROACH
• FIGURE 11 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ORGAN PRESERVATION MARKET (2025-2030)
• FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 13 DATA TRIANGULATION METHODOLOGY
• FIGURE 14 ORGAN PRESERVATION MARKET, BY SOLUTION, 2025 VS. 2030 (USD MILLION)
• FIGURE 15 ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2025 VS. 2030 (USD MILLION)
• FIGURE 16 ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2025 VS. 2030 (USD MILLION)
• FIGURE 17 ORGAN PRESERVATION MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• FIGURE 18 GEOGRAPHIC ANALYSIS OF ORGAN PRESERVATION MARKET
• FIGURE 19 RISING NUMBER OF SOLID ORGAN TRANSPLANTS TO DRIVE ORGAN PRESERVATION MARKET
• FIGURE 20 UNIVERSITY OF WISCONSIN SOLUTION AND CHINA SEGMENTS ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC ORGAN PRESERVATION MARKET IN 2024
• FIGURE 21 CHINA TO REGISTER FASTEST GROWTH DURING FORECAST PERIOD
• FIGURE 22 NORTH AMERICA TO DOMINATE ORGAN PRESERVATION MARKET TILL 2030
• FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
• FIGURE 24 ORGAN PRESERVATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 25 ORGAN PRESERVATION MARKET: ECOSYSTEM ANALYSIS
• FIGURE 26 ORGAN PRESERVATION MARKET: VALUE CHAIN ANALYSIS
• FIGURE 27 SUPPLY CHAIN ANALYSIS: ORGAN PRESERVATION MARKET (2024)
• FIGURE 28 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR ORGAN PRESERVATION SOLUTIONS (JANUARY 2014-APRIL 2025)
• FIGURE 29 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR ORGAN PRESERVATION PATENTS, 2014-2025
• FIGURE 30 ORGAN PRESERVATION MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 SOLUTIONS
• FIGURE 32 KEY BUYING CRITERIA FOR TOP 3 SOLUTIONS
• FIGURE 33 TRENDS AND DISRUPTIONS DISRUPTING CUSTOMER BUSINESS IN ORGAN PRESERVATION MARKET
• FIGURE 34 ORGAN PRESERVATION MARKET: INVESTMENT AND FUNDING SCENARIO, 2021-2024
• FIGURE 35 ORGAN PRESERVATION MARKET: AI INTEGRATION
• FIGURE 38 ASIA PACIFIC: ORGAN PRESERVATION MARKET SNAPSHOT
• FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS IN ORGAN PRESERVATION MARKET (2021-2024)
• FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS (2024)
• FIGURE 41 ORGAN PRESERVATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 42 ORGAN PRESERVATION MARKET: COMPANY FOOTPRINT
• FIGURE 43 ORGAN PRESERVATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 44 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 45 EV/EBITDA OF KEY VENDORS
• FIGURE 46 ORGAN PRESERVATION MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 47 XVIVO PERFUSION AB: COMPANY SNAPSHOT (2024)
• FIGURE 48 TRANSMEDICS, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 49 BIOLIFE SOLUTIONS, INC.: COMPANY SNAPSHOT (2024)

The global organ preservation market is projected to reach USD 0.3 billion by 2030 from USD 0.2 million in 2025, at a CAGR of 6.8% during the forecast period.

The primary objective of organ preservation solutions and devices is to maintain the viability and functionality of organs between procurement and transplantation. Several factors fuel consistent growth in this market, including the increasing volume of organ transplants globally, technological advancements in preservation techniques, and the introduction of specialized solutions such as hypothermic and normothermic machine perfusion systems. The growing incidence of chronic diseases such as end-stage renal and liver failure is driving the demand for organ transplants, which in turn boosts the need for effective preservation technologies.

By solution type, the University of Wisconsin (UW) segment accounted for the largest market share in 2024.

The market is categorized into UW, Custodiol HTK, Perfadex, and other solutions by solution type. In 2024, the University of Wisconsin (UW) solution accounted for the largest market share owing to high adoption and features such as proven efficacy in preserving organs like the liver, kidneys, and pancreas. It was the first introduced intracellular preservation solution and is widely regarded as the global benchmark for organ preservation. Its established clinical outcomes and reliability have solidified its position as the preferred choice among transplant surgeons and healthcare facilities.

By technique, the normothermic machine perfusion segment is expected to register the highest CAGR during the forecast period.

The normothermic machine perfusion segment is expected to grow at the highest CAGR during the forecast period. This technique simulates natural physiological conditions by maintaining normal body temperature and supplying essential nutrients and oxygen to the organ. It supports cellular function and metabolism throughout the preservation period. Normothermic perfusion helps maintain organ viability and minimizes inflammatory responses and ischemic injury, particularly in liver transplants. It is vital in improving graft regeneration and has been associated with better outcomes in transplant cases involving extended criteria donors, such as older individuals or those with comorbidities. As a result, its relevance is growing among transplant professionals seeking to optimize long-term graft survival and function.

By organ type, the lungs segment is expected to grow at the highest CAGR during the forecast period.

The lungs segment is expected to grow at the highest CAGR during the forecast period. Lung transplantation is regarded as the preferred treatment for patients with end-stage lung diseases such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, or cystic fibrosis, all of which contribute to the growth of this segment. Other common causes of end-stage lung disease in adult patients include alpha-1 antitrypsin deficiency and pulmonary hypertension. With the increasing prevalence of respiratory illnesses, the number of patients requiring lung transplants is anticipated to rise, thereby driving demand for lung transplants. Additionally, advancements in graft survival and long-term graft function have established lung transplantation as a vital and often life-saving therapeutic option.

By end user, the specialty clinics segment is expected to grow at the highest CAGR during the forecast period.

The organ preservation market is segmented by end-users into organ transplant centers, hospitals, and specialty clinics. The specialty clinics segment is projected to grow at the highest CAGR in the organ preservation market due to their increasing role in transplant procedures and post-operative care. These clinics offer focused expertise, faster turnaround times, and advanced technologies tailored to organ preservation needs. Additionally, growing patient preference for specialized care and the rise in private healthcare investments further accelerate their growth in this segment.

By region, the Asia Pacific is expected to grow at the highest CAGR during the forecast period.

The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The high growth rate of this segment is primarily attributed to the combination of favorable government policies, increased public awareness, and a higher number of organ donations. For instance, China has seen its donation rates improve thanks to intensified public education, mobilization efforts, and technological advancements in organ transplants. Meanwhile, India's rapid development in healthcare infrastructure has supported market growth and fostered medical tourism. Even with religious considerations, Japan has observed an improvement in organ donation due to a higher willingness to donate organs.

The breakdown of primary participants was as mentioned below:

• By Company Type - Tier 1-35%, Tier 2-45%, and Tier 3-20%
• By Designation - C-level-35%, Director-level-25%, Others-40%
• By Region - North America-45%, Europe-30%, Asia Pacific-20%, Latin America- 3%, the Middle East & Africa-1%, and GCC countries-1%

Key Players in the Organ Preservation Market

The key players operating in the organ preservation market include Paragonix Technologies (US), XVIVO Perfusion AB (Sweden), Dr. Franz Kohler Chemie GmbH (Germany), Essential Pharmaceuticals, LLC (US), TransMedics (US), OrganOx Limited (UK), 21st Century Medicine (US), Shanghai Genext Medical Technology (China), Bridge to Life Limited (US), Waters Medical Systems (US), Preservation Solutions (US), Carnamedica (Poland), Transplant Biomedicals (Spain), Institut Georges Lopez (France), Global Transplant Solutions (US), Avionord (Italy), Organ Preservation Solutions (England), EBERS (Spain), S.A.L.F. (Italy), Biochefa (Poland), Vascular Perfusion Solutions (US), and TX Innovations (Netherlands).

Research Coverage:

The report analyzes the organ preservation market and aims to estimate the market size and future growth potential based on various segments such as solution, technique, organ type, end user, and region. The report also includes a product portfolio matrix of various organ preservation products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which in turn would help them garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

Analysis of key drivers (Ascending cases of multiple organ failure and growth in the geriatric population, the increasing initiatives to promote public awareness and encourage organ donation, the rising number of organ donors boost adoption of solid organ transplantation procedures); restraints (High cost of organ transplantation and religious concerns and misconceptions associated to organ donation); opportunities (the increasing focus on healthcare investments); and challenges (Significant gap between the number of organs donated and organs required annually coupled with the development of artificial organs)

• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global organ preservation market. The report analyzes this market by solution, technique, organ type, and end user.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global organ preservation market
• Market Development: Comprehensive information on the lucrative emerging markets by solution type, technique, organ type, and end user
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global organ preservation market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global organ preservation market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
• 2.2 RESEARCH DESIGN
  • 2.2.1 SECONDARY RESEARCH
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Key data from primary sources
    • 2.2.2.2 Key industry insights
• 2.3 MARKET SIZE ESTIMATION
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 MARKET RANKING ANALYSIS
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
  • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.7.2 SCOPE-RELATED LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN ORGAN PRESERVATION MARKET
• 4.2 ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY SOLUTION AND COUNTRY
• 4.3 ORGAN PRESERVATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 ORGAN PRESERVATION MARKET, BY REGION, 2023-2030
• 4.5 ORGAN PRESERVATION MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing geriatric population and subsequent growth in cases of multiple organ failure
    • 5.2.1.2 Increasing initiatives to promote public awareness and encourage organ donation
    • 5.2.1.3 Rising number of organ donors and growing adoption of solid organ transplantation procedures
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of organ transplantation
    • 5.2.2.2 Religious concerns and misconceptions associated with organ donation
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing healthcare investments
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Significant gap between number of organs donated and organs required annually
    • 5.2.4.2 Development of artificial organs
• 5.3 ECOSYSTEM ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 PRICING ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 PATENT ANALYSIS
  • 5.7.1 PATENT PUBLICATION TRENDS FOR ORGAN PRESERVATION MARKET
  • 5.7.2 TOP APPLICANTS (COMPANIES) OF ORGAN PRESERVATION PATENTS
  • 5.7.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN ORGAN PRESERVATION MARKET
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 KEY TECHNOLOGIES
    • 5.8.1.1 Machine perfusion
    • 5.8.1.2 Organ perfusion
  • 5.8.2 ADJACENT TECHNOLOGIES
    • 5.8.2.1 Cryopreservation & vitrification
  • 5.8.3 COMPLEMENTARY TECHNOLOGIES
    • 5.8.3.1 Temperature monitoring devices
• 5.9 TRADE ANALYSIS
  • 5.9.1 IMPORT DATA
  • 5.9.2 EXPORT DATA
• 5.10 KEY CONFERENCES AND EVENTS IN 2025-2026
• 5.11 REGULATORY LANDSCAPE
  • 5.11.1 REGULATORY ANALYSIS
    • 5.11.1.1 North America
      • 5.11.1.1.1 US
      • 5.11.1.1.2 Canada
    • 5.11.1.2 Europe
    • 5.11.1.3 Asia Pacific
      • 5.11.1.3.1 China
      • 5.11.1.3.2 Japan
      • 5.11.1.3.3 India
    • 5.11.1.4 Latin America
      • 5.11.1.4.1 Brazil
      • 5.11.1.4.2 Mexico
    • 5.11.1.5 Middle East
    • 5.11.1.6 Africa
  • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 THREAT FROM NEW ENTRANTS
  • 5.12.2 THREAT FROM SUBSTITUTES
  • 5.12.3 BARGAINING POWER OF SUPPLIERS
  • 5.12.4 BARGAINING POWER OF BUYERS
  • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 BUYING CRITERIA
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.15 CASE STUDY ANALYSIS
• 5.16 INVESTMENT AND FUNDING SCENARIO
• 5.17 REIMBURSEMENT SCENARIO
• 5.18 IMPACT OF AI ON ORGAN PRESERVATION MARKET
• 5.19 END USER EXPECTATIONS IN ORGAN PRESERVATION MARKET
• 5.20 IMPACT OF 2025 US TARIFFS
  • 5.20.1 INTRODUCTION
  • 5.20.2 KEY TARIFF RATES
  • 5.20.3 PRICE IMPACT ANALYSIS
  • 5.20.4 IMPACT ON END USERS

6 ORGAN PRESERVATION MARKET, BY SOLUTION

• 6.1 INTRODUCTION
• 6.2 UNIVERSITY OF WISCONSIN
  • 6.2.1 METABOLICALLY INERT SUBSTRATES ENABLE BETTER TRANSPLANTATION OUTCOMES
• 6.3 CUSTODIOL HTK
  • 6.3.1 INDICATED FOR PERFUSION AND FLUSHING OF KIDNEYS, LIVER, PANCREAS, AND HEART
• 6.4 PERFADEX
  • 6.4.1 LAUNCH OF PERFADEX PLUS TO DRIVE MARKET
• 6.5 OTHER SOLUTIONS

7 ORGAN PRESERVATION MARKET, BY TECHNIQUE

• 7.1 INTRODUCTION
• 7.2 STATIC COLD STORAGE
  • 7.2.1 MOST WIDELY ADOPTED ORGAN PRESERVATION TECHNIQUE
• 7.3 HYPOTHERMIC MACHINE PERFUSION
  • 7.3.1 ADVANTAGES ASSOCIATED WITH HYPOTHERMIC MACHINE PERFUSION TO DRIVE DEMAND
• 7.4 NORMOTHERMIC MACHINE PERFUSION
  • 7.4.1 PROVIDES VIABLE ENVIRONMENT FOR ORGAN PRESERVATION, VIABILITY, AND REPAIR PRIOR TO TRANSPLANTATION

8 ORGAN PRESERVATION MARKET, BY ORGAN TYPE

• 8.1 INTRODUCTION
• 8.2 KIDNEYS
  • 8.2.1 MOST TRANSPLANTED ORGANS GLOBALLY
• 8.3 LIVER
  • 8.3.1 RISING PREVALENCE OF LIVER DISEASE AND GROWING CASES OF LIVER FAILURE TO DRIVE DEMAND FOR LIVER TRANSPLANTATION PROCEDURES
• 8.4 LUNGS
  • 8.4.1 GROWTH IN COPD INCIDENCE TO BOOST DEMAND FOR PRESERVATION TECHNIQUES AND PRODUCTS
• 8.5 HEART
  • 8.5.1 ADVANCEMENTS IN HEART PRESERVATION TECHNIQUES TO DRIVE MARKET
• 8.6 OTHER ORGANS

9 ORGAN PRESERVATION MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 ORGAN TRANSPLANT CENTERS
  • 9.2.1 MAJOR END USERS OF ORGAN PRESERVATION SOLUTIONS
• 9.3 HOSPITALS
  • 9.3.1 INCREASING CASES OF ACCIDENTAL INJURIES AND CHRONIC DISEASES TO DRIVE MARKET
• 9.4 SPECIALTY CLINICS
  • 9.4.1 INCREASING PREVALENCE OF END-STAGE DISEASES AND ORGAN FAILURE TO DRIVE MARKET

10 ORGAN PRESERVATION MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK
  • 10.2.2 US
    • 10.2.2.1 Growing cases of organ failure and underlying diseases to drive demand
  • 10.2.3 CANADA
    • 10.2.3.1 Improved organ donation rates to drive growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK
  • 10.3.2 GERMANY
    • 10.3.2.1 Growing patient population to drive demand
  • 10.3.3 FRANCE
    • 10.3.3.1 Increasing number of organ transplants and organ donor registrations to drive growth
  • 10.3.4 UK
    • 10.3.4.1 Increasing disease/disorder prevalence and favorable regulations to drive demand
  • 10.3.5 SPAIN
    • 10.3.5.1 High donation rates to drive growth
  • 10.3.6 ITALY
    • 10.3.6.1 Surge in donor numbers and technological innovation to drive growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK
  • 10.4.2 CHINA
    • 10.4.2.1 Growing awareness and adoption of laws favoring organ donation to drive market
  • 10.4.3 JAPAN
    • 10.4.3.1 Nationwide awareness campaigns and promoted opt-in registration to drive growth
  • 10.4.4 INDIA
    • 10.4.4.1 Growing number of initiatives to increase public awareness to drive market
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Enhanced hospital-based donation programs to drive growth
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Improved donor registration systems to drive growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK
  • 10.5.2 BRAZIL
    • 10.5.2.1 Digitalization of donor registries to drive growth
  • 10.5.3 MEXICO
    • 10.5.3.1 Organ donation efforts supported by centralized transplant registry and national coordination to drive growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 IMPLEMENTATION OF GOVERNMENT INITIATIVES AND POLICIES TO DRIVE MARKET
  • 10.6.2 MACROECONOMIC OUTLOOK
• 10.7 GCC COUNTRIES
  • 10.7.1 STRONG ORGAN PRESERVATION THROUGH INCENTIVES, INFRASTRUCTURE, AND PUBLIC AWARENESS TO DRIVE GROWTH
  • 10.7.2 MACROECONOMIC OUTLOOK

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 11.3 REVENUE ANALYSIS, 2022-2024
• 11.4 MARKET SHARE ANALYSIS
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Solution footprint
    • 11.5.5.3 Technique footprint
    • 11.5.5.4 End user footprint
    • 11.5.5.5 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.6.5.1 List of key startups/SMEs
    • 11.6.5.2 Competitive benchmarking of key startups/SMEs
• 11.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 11.7.1 COMPANY VALUATION
  • 11.7.2 FINANCIAL METRICS
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES & APPROVALS
  • 11.9.2 DEALS
  • 11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 PARAGONIX TECHNOLOGIES, INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches
      • 12.1.1.3.2 Deals
      • 12.1.1.3.3 Other developments
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 XVIVO PERFUSION AB
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches & approvals
      • 12.1.2.3.2 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 DR. FRANZ KOHLER CHEMIE GMBH
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 MnM view
      • 12.1.3.3.1 Right to win
      • 12.1.3.3.2 Strategic choices
      • 12.1.3.3.3 Weaknesses and competitive threats
  • 12.1.4 ESSENTIAL PHARMACEUTICALS, LLC (SUBSIDIARY OF ACCORD HEALTHCARE)
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 MnM view
      • 12.1.4.3.1 Right to win
      • 12.1.4.3.2 Strategic choices
      • 12.1.4.3.3 Weaknesses and competitive threats
  • 12.1.5 TRANSMEDICS, INC.
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches & approvals
      • 12.1.5.3.2 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Right to win
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 ORGANOX LIMITED
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches & approvals
      • 12.1.6.3.2 Deals
  • 12.1.7 21ST CENTURY MEDICINE
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
  • 12.1.8 BIOLIFE SOLUTIONS, INC.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product launches
      • 12.1.8.3.2 Deals
  • 12.1.9 BRIDGE TO LIFE LIMITED
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches & approvals
      • 12.1.9.3.2 Deals
  • 12.1.10 WATERS MEDICAL SYSTEMS LLC
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 SHANGHAI GENEXT MEDICAL TECHNOLOGY CO., LTD.
  • 12.2.2 PRESERVATION SOLUTIONS, INC.
  • 12.2.3 CARNAMEDICA
  • 12.2.4 TRANSPLANT BIOMEDICALS
  • 12.2.5 INSTITUT GEORGES LOPEZ
  • 12.2.6 GLOBAL TRANSPLANT SOLUTIONS
  • 12.2.7 AVIONORD
  • 12.2.8 ORGAN PRESERVATION SOLUTIONS LTD.
  • 12.2.9 EBERS
  • 12.2.10 S.A.L.F.
  • 12.2.11 BIOCHEFA
  • 12.2.12 VASCULAR PERFUSION SOLUTIONS, INC.
  • 12.2.13 TX INNOVATIONS
  • 12.2.14 TAIYO NIPPON SANSO CORPORATION
  • 12.2.15 X-THERMA, INC.

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 AVAILABLE CUSTOMIZATIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS